Format

Send to

Choose Destination
Pharm Pat Anal. 2014 Jul;3(4):449-66. doi: 10.4155/ppa.14.23.

Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases.

Abstract

The family of JAK comprises four members and has received significant attention in recent years from the pharmaceutical industry as a therapeutic target. The role of JAK is central to cytokine signaling pathways. It is believed that selective modulation of one specific JAK can lead to the inhibition of a restricted set of cytokines, which should avoid undesired side effects and get closer to the profile of biologic therapies. Consequently, selective JAK inhibition has become a major focus area of drug discovery research. A review of the TYK2 patents indicates that industry attention has recently turned toward the development of specific inhibitors. Importantly, despite the increasing number of published patents, none of these drugs have yet made it to the clinical trials.

PMID:
25291316
DOI:
10.4155/ppa.14.23
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center